U.S. markets open in 6 hours 6 minutes
  • S&P Futures

    4,376.00
    +27.75 (+0.64%)
     
  • Dow Futures

    34,112.00
    +273.00 (+0.81%)
     
  • Nasdaq Futures

    15,085.50
    +76.00 (+0.51%)
     
  • Russell 2000 Futures

    2,195.50
    +18.70 (+0.86%)
     
  • Crude Oil

    71.13
    +0.84 (+1.20%)
     
  • Gold

    1,760.20
    -3.60 (-0.20%)
     
  • Silver

    22.22
    +0.05 (+0.23%)
     
  • EUR/USD

    1.1736
    +0.0008 (+0.07%)
     
  • 10-Yr Bond

    1.3090
    0.0000 (0.00%)
     
  • Vix

    25.71
    +4.90 (+23.55%)
     
  • GBP/USD

    1.3683
    +0.0024 (+0.17%)
     
  • USD/JPY

    109.6870
    +0.2670 (+0.24%)
     
  • BTC-USD

    42,897.29
    -2,567.54 (-5.65%)
     
  • CMC Crypto 200

    1,073.80
    -60.58 (-5.34%)
     
  • FTSE 100

    6,953.18
    +49.27 (+0.71%)
     
  • Nikkei 225

    29,839.71
    -660.34 (-2.17%)
     

OCGN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Ocugen, Inc.

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - July 27, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Ocugen, Inc. ("Ocugen") (NASDAQ: OCGN) between February 2, 2021 and June 10, 2021.

If you suffered a loss, contact us at the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/ocugen-inc-loss-submission-form?prid=18011&wire=5

Allegations against OCGN include that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the information submitted to the U.S. Food and Drug Administration ("FDA") was insufficient to support an Emergency Use Authorization ("EUA"), (ii) Ocugen would not file an EUA with the FDA, (iii) as a result of the foregoing, the Company's financial statements, as well as Defendants' statements about Ocugen's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

If you suffered a loss in Ocugen you have until August 17, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/91341